Hemlibra Fatalities Now at 23!

Updated: Jul 22

Well, like clockwork, Genentech has released the quarterly fatalities report for Hemlibra.(Emicizumab)


A few weeks ago, we published a post about the New England Journal of Medicine publishing a letter to the Editor from Louis M. Aledort, M.D.


Dr. Aledort stated that " It is understandable that both patients with hemophilia A and their physicians are enthusiastic about the potential advantages of subcutaneous administration of emicizumab. However, I am concerned that we may be seeing the beginning of a serious public health issue. This population of patients has already been exposed to risks associated with therapy, and we should embrace this very important biologic agent with caution. "


We will be following up next quarter on the next fatalities report. The number will mostly likely be over 30. Anyone wanna start placing bets?

https://www.emicizumabinfo.com/content/dam/gene/emicizumabinfo/hcp/pdfs/fatalities.pdf

Subscribe and Get Breaking News Sent to Your Inbox!

  • White Instagram Icon
  • White Facebook Icon

© 2019- 2020 HEMO TIMES IS A SUBSIDIARY OF RARE HEALTH NETWORK, LLC